Literature DB >> 18981552

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.

Walid Shaib1, Frederick Lansigan, Daniel Cornfeld, Kostas Syrigos, Muhammad Wasif Saif.   

Abstract

CONTEXT: Gemcitabine is a pyrimidine antimetabolite with activity in a number of cancers. Gemcitabine is the accepted standard for the adjuvant and metastatic treatment of pancreatic cancer, however, it also has indications in breast, ovarian, and non-small cell lung cancers. The most common side effect is myelosuppression. Dyspnea is reported in 23% and bronchospasm occurs in less than 2% of subjects. Acute respiratory distress syndrome is rare with single agent use or in combination. CASE REPORT: A 68-year-old man being treated for stage IIA pancreatic cancer after pancreaticoduodenectomy developed hypoxemic respiratory distress after the second dose of gemcitabine 1,000 mg/m(2). The radiographic findings on computed tomography scans evolved from ground glass opacities to findings suggestive of cryptogenic organizing pneumonia over the course of two weeks. He was treated with antibiotics, steroids, nebulizers and oxygen. A follow-up computed tomography scan of chest four weeks after presentation showed complete resolution of pneumonitis.
CONCLUSIONS: We report the first case of gemcitabine-induced pneumonitis encountered during the adjuvant treatment of pancreatic cancer. Physicians seeing such patients should be aware of this rare but real pulmonary toxicity. A delay in diagnosis and treatment can lead to potentially fatal outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981552

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  10 in total

1.  Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.

Authors:  Shigeki Umemura; Hiromichi Yamane; Toshimitsu Suwaki; Tsutomu Katoh; Takuya Yano; Yasuhiro Shiote; Nagio Takigawa; Katsuyuki Kiura; Haruhito Kamei
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-05       Impact factor: 4.553

2.  Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

Authors:  Ibrahim Halil Sahin; Alexander I Geyer; Daniel W Kelly; Eileen Mary O'Reilly
Journal:  Clin Colorectal Cancer       Date:  2015-08-22       Impact factor: 4.481

3.  BOOP as a rare complication of gemcitabine therapy.

Authors:  Hameem I Kawsar; Timothy P Spiro; Amy Cocco; Hamed A Daw
Journal:  BMJ Case Rep       Date:  2011-07-20

4.  Interstitial pneumonitis from treatment with gemcitabine.

Authors:  Brolin B Poole; Leslie A Hamilton; Megan M Brockman; Debbie C Byrd
Journal:  Hosp Pharm       Date:  2014-10

5.  Pulmonary Tuberculosis Versus Recurrent Chemotherapy-Induced Pneumonitis: A Clinical Dilemma.

Authors:  Gulrayz Ahmed; Muhammad W Saif
Journal:  Cureus       Date:  2017-10-04

6.  A case of late-onset gemcitabine lung toxicity.

Authors:  Amanda M Sherrod; Adam Brufsky; Shannon Puhalla
Journal:  Clin Med Insights Oncol       Date:  2011-05-29

7.  High-resolution computed tomography illustrating pulmonary lymphangitic carcinomatosis in a patient with advanced pancreatic cancer: a case report.

Authors:  Liao Wan-Hsiu; Lin Sheng-Hsiang; Wu Tsu-Tuan
Journal:  Cases J       Date:  2009-05-12

8.  Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.

Authors:  Flávio Henrique Ferreira Galvão; José Osmar Medina Pestana; Vera Luiza Capelozzi
Journal:  Cancer Chemother Pharmacol       Date:  2010-02       Impact factor: 3.333

9.  Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.

Authors:  Célia Turco; Marine Jary; Stefano Kim; Mélanie Moltenis; Bruno Degano; Philippe Manzoni; Thierry Nguyen; Bruno Genet; Marie-Blanche Valnet Rabier; Bruno Heyd; Christophe Borg
Journal:  Clin Med Insights Oncol       Date:  2015-09-01

10.  Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report.

Authors:  Francesca Comito; Elisa Grassi; Antonio Poerio; Eva Freier; Lucia Calculli; Maurizio Zompatori; Claudio Ricci; Riccardo Casadei; Mariacristina Di Marco
Journal:  BJR Case Rep       Date:  2018-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.